|
WO2020123481A1
|
|
Combination formulations of taxanes and mtor inhibitors
|
|
AU2019350759A1
|
|
Low-intensity treatment of hematological disorders
|
|
MX2018005771A
|
|
Assays and methods for selecting a treatment regimen for a subject with leukemia.
|
|
KR20180029242A
|
|
Improved nanoparticle delivery system
|
|
AU2012326370A1
|
|
Lyophilized liposomes
|
|
EP2344161A1
|
|
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
|
CN101878024A
|
|
Improved taxane delivery system
|
|
WO2009097011A1
|
|
Improved platinum drug formulations
|
|
WO2008101214A2
|
|
Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
|
|
AU2007237323A1
|
|
Compositions for delivery of drug combinations
|
|
WO2007076117A2
|
|
Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
|
|
EP1959940A2
|
|
Localized delivery of drug combinations
|
|
EP1951239A2
|
|
Fixed ratio drug combination treatments for solid tumors
|
|
CN101330917A
|
|
Fixed ratio drug combination treatments for solid tumors
|
|
EP1937283A2
|
|
Combination formulations of cytidine analogs and platinum agents
|
|
EP1848404A2
|
|
Lipid carrier compositions with reduced polydispersity
|
|
EP1817005A1
|
|
Method for loading multiple agents into delivery vehicles
|
|
CA2574767A1
|
|
Particulate constructs for release of active agents
|
|
CA2564542A1
|
|
Combination formulations of anthracycline agents and cytidine analogs
|
|
CA2536612A1
|
|
Combination compositions of camptothecins and fluoropyrimidines
|
